CD276 and cancer: This hypothesis is supported by our previous study examining adjuvant chemotherapy, which found that patients with high B7‐H3 expression on final radical cystectomy specimens had significantly worse recurrence‐free survival (HR: 2.38, 95% CI 1.06–5.31, p = 0.035) and cancer‐specific survival (HR: 2.67, 95% CI 1.18–6.04, p = 0.019) compared to those with low or no B7‐H3 expression.12